Navigation Links
TEI Biosciences Launches SurgiMend(TM) Collagen Matrix for Soft Tissue Reconstruction
Date:10/17/2007

BOSTON, Oct. 17 /PRNewswire/ -- TEI Biosciences Inc. announces the launch of its SurgiMend(TM) Collagen Matrix for Soft Tissue Reconstruction product. TEI has received 510(k) clearance from the U.S. Food and Drug Administration to market SurgiMend for expanded use in plastic and reconstructive surgery, including breast reconstruction, and for tendon augmentation, in addition to the previously cleared hernia repair and muscle flap reinforcement indications.

"SurgiMend has been the biologic material of choice for many general, plastic, and trauma surgeons for their hernia repair and muscle flap reinforcement needs. With multiple indications, excellent handling and suturing characteristics, and a rapid hydration rate that saves valuable operating room time, SurgiMend has the potential to become the medical community's primary choice for soft tissue repair and reconstruction. In addition, SurgiMend provides an opportunity for hospitals to cover a broad range of applications with a single biologic device at a single price point," said Yiannis Monovoukas, Ph.D., TEI's Chairman, President, and CEO.

SurgiMend is an acellular, terminally sterilized biologic matrix derived from the dermis of fetal calves, one of the purest sources of collagen available. It is intrinsically strong yet soft and pliable when hydrated, and handles like natural tissue; it readily conforms to the surgical site and is easily sutured. SurgiMend is rich in Type III collagen, the active collagen found in developing and healing tissues. It is not artificially crosslinked and its biochemistry and microporosity facilitate rapid cell penetration, revascularization, and integration with host tissues. SurgiMend is available in multiple sizes, both large and small, and can be stored dry at room temperature for up to three years.

SurgiMend will be on display at the American Society of Plastic Surgeons meeting in Baltimore, MD, October 29-30, at booth # 145.

About TEI Biosciences

A Boston-based, privately-held, leading biomedical company, TEI Biosciences Inc. (http://www.teibio.com) has applied its expertise in regenerative medicine to develop and commercialize novel biologic products for a broad spectrum of soft tissue repair and reinforcement applications -- from dura, tendon, and hernia repair to wound management and plastic and reconstructive surgery.

TEI sells its products directly and through partnerships with some of the world's major medical device companies. In addition to SurgiMend, TEI's marketed products include:

PriMatrix(TM) for skin wound management;

Durepair(R) for cranial and spinal dura mater repair;

Xenform(TM) for pelvic floor reconstruction; and

TissueMend(R) for tendon augmentation.

For further information, please contact:

Yiannis Monovoukas, Ph.D.

ymonovoukas@teibio.com

or

Tony Russo, Ph.D.

Russo Partners, LLC

(212) 845-4251

tony.russo@russopartnersllc.com.


'/>"/>
SOURCE TEI Biosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... Toronto, Canada (PRWEB) , ... May 23, 2017 ... ... of Firmex FileSend, a cloud-based file transfer solution that makes it easy for ... firewall without having to worry about cumbersome FTP software or email file size ...
(Date:5/23/2017)... Ca (PRWEB) , ... May ... ... (PSCs) offer an unlimited source of human cardiovascular cells for research and ... differentiation methods makes it possible to generate large numbers of cardiomyocytes (hPSC-CMs). ...
(Date:5/23/2017)... ... 2017 , ... NetDimensions has been ranked as a Leader ... Corporate Learning, 2017. , Aragon Research defines Leaders as organizations who possess comprehensive ... those strategies. NetDimensions’ ranking as a Leader due to its strengths in: , ...
(Date:5/23/2017)... PARK, CA (PRWEB) , ... May 23, 2017 , ... ... the publication of “Label-free isolation of prostate circulating tumor cells using Vortex microfluidic ... is the result of a collaboration with Dr. Dino Di Carlo and Dr. Matthew ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):